Tammy L. Gomez
Known title: Chief Human Resources OfficerCIK: 0001937481
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Transaction History
| SOLV | ▲ Buy | Option Exercise | 3,960 | $0 | 5/13/2026 | View on chart |
| SOLV | ▼ Sell | Tax Withholding | 1,668 | $124K | 5/13/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,300 | $0 | 3/6/2026 | View on chart |
| SOLV | ▼ Sell | Tax Withholding | 895 | $62K | 3/6/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 4,342 | — | 1/2/2026 | View on chart |
| SOLV | ▼ Sell | Tax Withholding | 1,332 | $105K | 1/2/2026 | View on chart |
| SOLV | ▼ Sell | Tax Withholding | 1,298 | $95K | 5/13/2025 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,959 | $0 | 5/13/2025 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 4,342 | $0 | 1/2/2025 | View on chart |
| SOLV | ▼ Sell | Tax Withholding | 1,348 | $89K | 1/2/2025 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 1,506 | $30K | 8/15/2023 | View on chart |
| ACH | ▲ Buy | Grant | 32,384 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 15,904 | $0 | 7/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists
Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.